BioCurex, Inc.(fka BOCX)

[Gold Seeker]

Gaboy, actually Abbott obviously had more than one objection. First, they stated in the ISOBM abstract that they wanted the cancer / normal ratio higher. That is what I had mentioned before, more definition beteen positives and negatives, i.e., a more accurate test.

The filings show that Dr. Moro was working on reducing the cost of the test and higher shelf life. I have just been stating that I think Abbott is concerned about how they spend money right now and probably the economics of the test and anticipated market may not have mated up for them and their overall objectives.